Institute for Cancer Research

Kjetil Taskén
Instiute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

Annual report 2017 (pdf):
download in single page format - double page (broad) format

Publication overview

Current news and events

Ceremony Friday November 23rd:Ragnar Mørk legacy prize 2018 to Kaisa Haglund

Kaisa Haglund

The 2018 "Dr. Ragnar Mørk's legacy prize" goes to Kaisa Haglund, head of the "Cytokinesis in development and carcinogenesis project group" at the Department of Molecular Cell Biology, for her outstanding research on cell division and cancer..
This award of NOK 200.000 is annually given to scientists affiliated to the Norwegian Radium Hospital who have obtained important results within the field of cancer research.
The ceremony will take place on Friday November 23rd in seminar rooms 1+2 om the Research Building at Montebello, starting at 14:30.
Kaisa Haglund will then give a lecture about the research activities that has earned her the award.

 

Researchers at the Department of Immunology publish groundbreaking proteomics technology in Nature Methods.

Fridtjof Lund-Johansen (center) and co-workers

The prestigious journal Nature Methods recently published an article by proteomics researchers at the Department of Immunology. "We describe a simple and affordable method for large-scale protein analysis and test the specificity of 6000 commercially available antibodies to human proteins" says Fridtjof Lund-Johansen, who led the study.
The findings are drawing attention, and the major national news outlet for health and medicine "Dagens Medisin" has covered the story.

Proteins are the building blocks of cells and tissues, and they operate in complex clockworks to exert a host of biological functions. The purpose of large-scale protein analysis, or proteomics, is to dissect these clockworks and understand how they operate. Most drugs act by modifying the function of one or more proteins, so there is good reason to believe that insight from proteomics research will open new avenues for therapy.

Molecular Oncology cover features work by the Russnes group

Tissue section from a HER2 positive breast carcinoma stained by ImmunoFISH reveals extensive intratumor heterogeneity. Image by I. H. Rye/H. Russnes.

The latest issue of Molecular Oncology features an ImmunoFISH image from the article “Intratumor heterogeneity defines treatment resistant HER2+ breast tumors”, as their cover image.

In the article published in the same issue Inga H. Rye, post doc in the Russnes group, combined immunofluorescence and in situ hybridization (ImmunoFISH) on tissue sections and analyzed more than 13 000 single tumor cells from 37 HER2+ breast tumors. By a validated computational approach previously developed by the group (GoIFISH, Trinh et al. Genome Biology 2016), they found a subset of HER2+ breast carcinomas to exhibit substantial heterogeneity with regard to HER2 protein expression, HER2 gene copy number alteration, and estrogen receptor protein expression. 

Skotheim group publishes important prostate cancer study in prestigious journal:High degree of genomic heterogeneity in multifocal primary prostate cancer

Marthe Løvf
First author

The vast majority of primary prostate cancers are multifocal. The individual tumors within the prostate gland are known to have different aggressiveness and develop independently of one another, but little has been known about their genetic relationship.

Marthe Løvf and colleagues have performed the first large in-depth genomic heterogeneity study of primary prostate cancer and the results were published in the recognized journal European Urology earlier this month. The researchers performed exome sequencing of 89 tumor foci from 41 patients and demonstrated convincingly that the different foci within the same patient only exceptionally have any somatic gene mutations in common.

Units and subpages

View all subunitsHide all subunits